Join UCI Health at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, May 29 to June 2 in Chicago, as we showcase how Orange County’s only academic health system is advancing the future of cancer care.

At the UCI Health Chao Family Comprehensive Cancer Center, a National Cancer Institute-designated comprehensive cancer center, we are bringing together nationally renowned physicians, scientists, and care teams to expand access to innovative therapies, multidisciplinary expertise and clinical trials for patients with complex and challenging cancers.

“ASCO remains an important forum for advancing precision oncology and sharing the insights that will shape more individualized cancer care,” said Richard Van Etten, MD, PhD, director of the UCI Health Chao Family Comprehensive Cancer Center. “At UCI Health, we are committed to translating those advances into stronger clinical trials access, multidisciplinary expertise, and leading-edge treatment options for patients across Orange County and beyond.”

Through translational research, precision medicine and advanced treatment approaches, UCI Health is helping move promising discoveries more quickly from bench to bedside.

Friday, May 29

ALKOVE-1: Efficacy and safety of neladalkib in patients with advanced ALK+ NSCLC.
Presenter: Jessica Jiyeong Lin, MD (Mass General Brigham Cancer Institute)
Co-authors: Misako Nagasaka, MD, PhD
Time: 2:12 - 2:24 p.m.
Location: Hall D2 | Live Stream
Session Type: Oral Abstract Session
Track(s): Lung Cancer—Non-Small Cell Metastatic
Abstract: 8503

Enfortumab vedotin plus pembrolizumab vs chemotherapy for previously untreated locally advanced or metastatic urothelial carcinoma: 3.5-year follow-up and response analyses from the phase 3 EV-302 study.
Presenter: Thomas Powles, MD, PhD (Barts Cancer Centre, Queen Mary University of London)
Co-authors: Nataliya Mar, MD
Time: 4:45 - 4:57 p.m.
Location: Arie Crown Theater | Live Stream
Session Type: Oral Abstract Session
Track(s): Genitourinary Cancer—Kidney and Bladder
Abstract: 4507

Saturday, May 30

Phase 1 study of NTX1088, a first-in-class anti-PVR monoclonal antibody, as monotherapy and combined with pembrolizumab, in patients with advanced solid malignancies.
Presenter: Sarina A. Piha-Paul, MD, MS (The University of Texas MD Anderson Cancer Center)
Co-authors: Miguel Villalona-Calero, MD
Time: 9:00 - 9:06 a.m.
Location: E451
Session Type: Rapid Oral Abstract Session
Track(s): Developmental Therapeutics—Immunotherapy 
Abstract: 2518

A randomized phase II/III trial of intraperitoneal paclitaxel plus systemic treatment vs systemic treatment alone in gastric carcinomatosis: STOPGAP II—ECOG-ACRIN EA2234.
Presenter: Maheswari Senthil, MD, FACS
First author: Maheswari Senthil, MD, FACS
Co-authors: Farshid Dayyani, MD, PhD
Time: 9 a.m. - 12 p.m.
Location: Hall A - Posters and Exhibits | On Demand
Abstract: TPS4241
Poster board: 223a

Real-world treatment patterns and overall survival in patients with HER2-positive advanced or metastatic gastroesophageal adenocarcinomas in the United States.
Presenter: Farshid Dayyani, MD, PhD
First author: Farshid Dayyani, MD, PhD
Time: 9 a.m. - 12 p.m.
Location: Hall A - Posters and Exhibits | On Demand
Abstract: 4053
Poster board: 36

Phase I light-dose escalation study in locally advanced pancreatic ductal adenocarcinoma: Intra-arterial (IA) padeliporfin vascular-targeted photodynamic therapy (VTP).
Presenter: Nadine Abi-Jaoudeh, MD
First Author: Nadine Abi-Jaoudeh, MD
Co-authors: Jennifer Valerin, MD, PhD and Zeljka Jutric, MD
Time: 9 a.m. - 12 p.m.
Location: Hall A - Posters and Exhibits | On Demand
Abstract: TPS4267
Poster board: 236a

Final results and preliminary correlative analysis of a phase I study of anetumab ravtansine in combination with checkpoint inhibitors and gemcitabine in mesothelin-positive advanced pancreatic adenocarcinoma (NCI10208).
Presenter: Carlos Diego Holanda Lopes, MD (University Health Network, University of Toronto)
Co-authors: Farshid Dayyani, MD, PhD
Time: 9 a.m. - 12 p.m.
Location: Hall A - Posters and Exhibits | On Demand
Abstract: 4205
Poster board: 188

TRIDENT: A phase 2 study of relacorilant plus nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic ductal adenocarcinoma.
Presenter: Erkut H. Borazanci, MD, MS (HonorHealth Research Institute)
Co-authors: Farshid Dayyani, MD, PhD
Time: 9 a.m. - 12 p.m.
Location: Hall A - Posters and Exhibits | On Demand
Abstract: TPS4263
Poster board: 234a

Phase 1 basket study of telisotuzumab adizutecan (Temab-A, ABBV-400), a c-Met protein-targeting antibody-drug conjugate: results from patients with head and neck squamous cell carcinoma (HNSCC).
Presenter: Victoria Villaflor, MD
First author: Victoria Villaflor, MD
Time: 1:30 - 4:30 p.m.
Location: Hall A - Posters and Exhibits | On Demand
Abstract: 6027
Poster board: 484

ETCTN 10302: A randomized phase II trial of radium-223 dichloride in combination with paclitaxel in patients with bone metastatic breast cancer.
Presenter: Jyoti Malhotra, MD, MPH (City of Hope)
Co-authors: Ritesh Parajuli, MD
Time: 1:30 - 4:30 p.m.
Location: Hall A - Posters and Exhibits | On Demand
Abstract: 3096
Poster board: 233

First-in-human trial of the TEAD inhibitor ODM-212 in patients with advanced solid tumors (TEADES).
Presenter: Johann S. De Bono, MD, PhD, MB, MSc (The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust)
Co-authors: Farshid Dayyani, MD, PhD
Time: 1:30 - 4:30 p.m.
Location: Hall A - Posters and Exhibits | On Demand
Abstract: 3111
Poster board: 248

BXQ-350 in combination with FOLFOX7 and bevacizumab: Evaluation of effect on oxaliplatin-induced CIPN and neutropenia—A phase 1b/2a trial to assess the efficacy and safety of BXQ-350, a first-in-class sphingolipid metabolism modulator, in newly diagnosed metastatic colorectal carcinoma.
Presenter: Tariq Arshad, MD, MBA (Bexion Pharmaceuticals)
Co-authors: Fa-Chyi Lee, MD
Time: 1:30 - 4:30 p.m.
Location: Hall A - Posters and Exhibits | On Demand
Abstract: 12080
Poster board: 63

MATRiX: A randomized phase II trial of tuvusertib (ATR inhibitor) with or without avelumab in advanced anti-PD(L)-1 refractory Merkel cell carcinoma.
Presenter: Evan Thomas Hall, MD, MPhil (Fred Hutchinson Cancer Center)
Co-authors: Ling Gao, MD, PhD
Time: 4:42 - 4:48 p.m.
Location: E451
Session Type: Rapid Oral Abstract Session
Track(s): Melanoma/Skin Cancers
Abstract: LBA9514

Sunday, May 31

Real-world clinical outcomes by HER2 expression in locally advanced or metastatic urothelial carcinoma: results from the global SGNDV-003 retrospective study.
Presenter: Vadim S. Koshkin, MD (University of California, San Francisco)
Co-authors: Nataliya Mar, MD
Time: 9 a.m. - 12 p.m.
Location: Hall A - Posters and Exhibits | On Demand
Abstract: 4562
Poster board: 41

Phase 2 study of metronomic cyclophosphamide with pembrolizumab in checkpoint inhibitor-refractory melanoma.
Presenter: Poorva Vaidya, MD
First author: Poorva Vaidya, MD
Time: 9 a.m. - 12 p.m.
Location: Hall A - Posters and Exhibits | On Demand
Abstract: TPS9599
Poster board: 481b

A phase 2 study of neoadjuvant nivolumab + relatlimab versus nivolumab in patients with resectable high-risk basal cell carcinoma.
Presenter: Soo J. Park, MD (University of California, San Diego)
Co-authors: Poorva Vaidya, MD
Time: 9 a.m. - 12 p.m.
Location: Hall A - Posters and Exhibits | On Demand
Abstract: TPS9613
Poster board: 488b

A phase II trial of ivonescimab for previously treated thymic carcinoma: UCLA L-11.
Presenter: Jonathan Boiarsky, MD (University of California, Los Angeles)
Co-authors: Zhaohui Arter, MD
Time: 9 a.m. - 12 p.m.
Location: Hall A - Posters and Exhibits | On Demand
Abstract: TPS8140
Poster board: 605b

A phase I/IIa, first-in-human, multicenter, monotherapy and combination therapy with nivolumab dose-finding study of [212Pb]VMT01 melanocortin-1-receptor–targeted, image-guided, alpha-particle therapy in subjects with previously treated unresectable or metastatic melanoma.
Presenter: Zachary Scott Morris, MD, PhD (University of Wisconsin)
Co-authors: Shyam Srinivas, MD
Time: 9 a.m. - 12 p.m.
Location: Hall A - Posters and Exhibits | On Demand
Abstract: 9525
Poster board: 241

ProTACT: A first-in-human, phase 1 dose escalation and expansion study evaluating the safety, tolerability, and anti-tumor activity of [225Ac]Ac-FL-020, a PSMA-targeted radioconjugate, in patients with mCRPC.
Presenter: Robert Dreicer, MD, MACP, MS, FASCO (University of Virginia School of Medicine)
Co-authors: Shyam Srinivas, MD
Time: 9 a.m. - 12 p.m.
Location: Hall A - Posters and Exhibits | On Demand
Abstract: TPS5141
Poster board: 231a

ProTACT: Preliminary data from a first-in-human, phase 1 study evaluating the safety, tolerability, and anti-tumor activity of [225Ac]Ac-FL-020, a PSMA-targeted radioconjugate, in patients with mCRPC.
Presenter: Alison Yan Zhang, PhD, FRACP, MBBS, MMed (Macquarie University)
Co-authors: Shyam Srinivas, MD
Time: 9 a.m. - 12 p.m.
Location: Hall A - Posters and Exhibits | On Demand
Abstract: 5050
Poster board: 145

Advancing treatment of low-grade upper tract urothelial carcinoma (LG UTUC) with padeliporfin vascular-targeted photodynamic therapy (VTP): The ENLIGHTED phase 3 trial.
Presenter: Vitaly Margulis (UT Southwestern Medical Center)
Co-authors: Edward M. Uchio, MD
Time: 9 a.m. - 12 p.m.
Location: Hall A - Posters and Exhibits | On Demand
Abstract: TPS4643
Poster board: 115a

A phase 2 study of ipatasertib in combination with pembrolizumab for first-line treatment of recurrent or metastatic squamous cell cancer of the head and neck.
Presenter: Jacob Stephen Thomas, MD (University of Southern California Norris Comprehensive Cancer Center)
Co-authors: Victoria Villaflor, MD
Time: 10:00 - 10:12 a.m.
Location: S100a | Live Stream
Session Type: Oral Abstract Session
Track(s): Head and Neck Cancer
Abstract: 6006

Impact of population-based testing for pathogenic variants in breast cancer genes on screening recommendations in the WISDOM study.
Presenter: Yiwey Shieh, MD (University of California, San Francisco)
Co-authors: Deborah Goodman-Gruen, MD, MPH, PhD
Time: 10:09 - 10:15 a.m.
Location: S403 | Live Stream
Session Type: Rapid Oral Abstract Session
Track(s): Prevention, Risk Reduction, and Genetics
Abstract: 10512

Monday, June 1

Emiltatug ledadotin (Emi-Le), a B7-H4-directed antibody-drug conjugate, in patients with aggressive adenoid cystic carcinoma: Phase 1 interim analysis. Clinical Science Symposium: Small Glands, Big Challenges: Novel Therapeutics in Salivary Gland Cancer.
Presenter: Glenn J. Hanna, MD (Dana-Farber Cancer Institute, Harvard Medical School)
Co-authors: Shirin Attarian, MD
Time: 8:24 - 8:36 a.m.
Location: E450b
Session Type: Clinical Science Symposium
Track(s): Head and Neck Cancer
Abstract: 6010

A phase 2 study of darolutamide plus leuprolide acetate in hormone-therapy naïve recurrent and/or metastatic androgen receptor-positive salivary gland cancer (ETCTN 10553).
Presenter: Alan Loh Ho, MD, PhD (Memorial Sloan Kettering Cancer Center)
Co-authors: Shirin Attarian, MD
Time: 8:48 - 9 a.m.
Location: E450b
Session Type: Clinical Science Symposium
Track(s): Head and Neck Cancer
Abstract: 6012

The role of combined T cell and NK cell activity in immune checkpoint inhibitor (ICI) therapy in endometrial cancer (EC).
Presenter: Danielle Greenberg, MD
First author: Danielle Greenberg, MD
Co-authors: Krishnansu Tewari, MD
Time: 9 a.m. - 12 p.m.
Location: Hall A - Posters and Exhibits | On Demand
Abstract: 5609
Poster board: 275

A phase 2 study of olutasidenib in combination with azacitidine followed by olutasidenib maintenance after venetoclax plus a hypomethylating agent regimen for IDH1-mutated acute myeloid leukemia (University of California Hematologic Malignancies Consortium Study 2441).
Presenter: Brian Andrew Jonas, MD, PhD (University of California, Davis)
Co-authors: Deepa Jeyakumar, MD
Time: 9 a.m. - 12 p.m.
Location: Hall A - Posters and Exhibits | On Demand
Abstract: TPS6603
Poster board: 394a

TroFuse-036/GOG-3123/ENGOT-cx22: A 2-part, phase 3, randomized study of sacituzumab tirumotecan (sac-TMT) + pembrolizumab (pembro) ± bevacizumab (bev) vs standard of care (SoC) as first-line maintenance therapy for PD-L1–positive cervical cancer.
Presenter: Brian Slomovitz, MD (Mount Sinai Medical Center)
Co-authors: Krishnansu Tewari, MD
Time: 9 a.m. - 12 p.m.
Location: Hall A - Posters and Exhibits | On Demand
Abstract: TPS5628
Poster board: 294a

Pirtobrutinib in treatment-naïve patients with CLL/SLL: Pooled results from BRUIN CLL-313 and BRUIN CLL-314.
Presenter: William G. Wierda, MD, PhD (The University of Texas MD Anderson Cancer Center)
Co-authors: Catherine Coombs, MD
Time: 9 a.m. - 12 p.m.
Location: Hall A - Posters and Exhibits | On Demand
Abstract: 7044
Poster board: 542

ADAM trial: A multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in patients with Merkel cell carcinoma and lymph node metastases.
Presenter: Shailender Bhatia, MD (Fred Hutchinson Cancer Center)
Co-authors: Ling Gao, MD, PhD
Time: 9:12 - 9:24 a.m.
Location: S100bc | Live Stream
Session Type: Oral Abstract Session
Track(s): Melanoma/Skin Cancers
Abstract: LBA9504

Does resection of cavity shave margins impact survival in breast cancer patients?
Presenter: Anees B. Chagpar, MD, MPH, MBA, MSc, MA, FACS, FRCS, FASCO (Yale School of Medicine)
Co-authors: Maheswari Senthil, MD, FACS
Time: 10:27 - 10:33 a.m.
Location: Hall D2 | Live Stream
Session Type: Clinical Science Symposium
Track(s): Breast Cancer—Local/Regional/Adjuvant
Abstract: 513

Neuropsychiatric symptom and biomarker changes with electroacupuncture in adolescent and young adult cancer survivors: Results from a randomized controlled trial.
Presenter: Alexandre Chan, PharmD, MPH
First author: Alexandre Chan, PharmD, MPH
Time: 1:30 - 4:30 p.m.
Location: Hall A - Posters and Exhibits | On Demand
Abstract: 10054
Poster board: 305

A phase 2 double-blind, randomized, prospective, placebo-controlled study of NanO? combined with radiation and temozolomide in patients with newly diagnosed glioblastoma: RESTORE.
Presenter: Samuel A. Goldlust, MD (Saint Luke's Cancer Institute)
Co-authors: Xiao-Tang Kong, MD
Time: 1:30 - 4:30 p.m.
Location: Hall A - Posters and Exhibits | On Demand
Abstract: 2065
Poster board: 430

Efficacy and safety of engineered TCR-T cell therapy (afami-cel, lete-cel) in pediatric synovial sarcoma.
Presenter: Amy E. Armstrong, MD (Washington University in St. Louis)
Co-authors: Warren Chow, MD
Time: 1:30 - 4:30 p.m.
Location: Hall A - Posters and Exhibits | On Demand
Abstract: 11569
Poster board: 359

Zongertinib combination therapy in HER2-positive metastatic breast cancer (mBC): First results from a phase Ib/II trial.
Presenter: Shigehisa Kitano, MD, PhD (Japanese Foundation for Cancer Research)
Co-authors: Farshid Dayyani, MD, PhD
Time: 1:30 - 4:30 p.m.
Location: Hall A - Posters and Exhibits | On Demand
Abstract: 1044
Poster board: 158

A phase II open-label, single-arm study to evaluate the efficacy of pembrolizumab for leukoplakia.
Presenter: Deborah J.L. Wong, MD, PhD (University of California, Los Angeles)
Co-authors: Mark Swanson, MD
Time: 1:30 - 4:30 p.m.
Location: Hall A - Posters and Exhibits | On Demand
Abstract: 10544
Poster board: 505

Tuesday, June 2

Treatment Options for Double-Exposed Chronic Lymphocytic Leukemia
Presenter: Susan Mary O'Brien, MD
Time: 8:30 - 8:45 a.m.
Location: S100a | Live Stream
Session Type: Education Session
Track(s): Hematologic Malignancies

First-in-human trial of BH-30643, a novel macrocyclic, non-covalent, mutant-selective OMNI-EGFR inhibitor, in EGFR-mutant (EGFRm) NSCLC.
Presenter: Xiuning Le, MD, PhD (The University of Texas MD Anderson Cancer Center)
Co-authors: Misako Nagasaka, MD, PhD
Time: 8:30 - 8:45 a.m.
Location: E451
Session Type: Rapid Oral Abstract Session
Track(s): Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Abstract: 3014

PUBLICATION ONLY 

Alex Francoeur

Immunotherapy use without approval: Patterns, biases, and biomarkers in patients with ovarian cancer. J Clin Oncol 44, 2026 (suppl 16; abstr e17588)

Meet Us

To schedule a meeting at ASCO, contact UCI Health senior manager of business development, Ken Salehi, by phone at 310-709-0108 or email salehk@hs.uci.edu

Connect With Us

@UCIPhysicians on X                                  

UCI Health Physicians on LinkedIn